MRPL19: A Potential Drug Target and Biomarker for Mitochondrial Disorders

Target Name: MRPL19

NCBI ID: G9801

MRPL19: A Potential Drug Target and Biomarker for Mitochondrial Disorders

Abstract:

Mitochondrial dysfunction is a neurodegenerative disorder that affects the power production by the mitochondria, leading to a range of symptoms, including cognitive impairments, fatigue, and muscle weakness. The 39S ribosomal protein L19 (MRPL19) is a protein that is expressed in the mitochondria and is involved in the assembly and function of the 39S ribosome, which is responsible for producing the majority of the proteins in the cell. The aim of this article is to discuss the potential drug target and biomarker properties of MRPL19, with a focus on its involvement in mitochondrial dysfunction and its potential as a therapeutic target.

Introduction:

Mitochondrial dysfunction is a complex neurodegenerative disorder that is characterized by a range of symptoms, including cognitive impairments, fatigue, muscle weakness, and neuroinflammation. The mitochondria are responsible for producing the majority of the energy in the cell and are also responsible for maintaining the structural integrity of the cells. When the mitochondria are damaged or dysfunctional, they are unable to produce enough energy, leading to a range of symptoms.

MRPL19: A Protein expression and function

MRPL19 is a protein expressed in eukaryotic cells and mainly exists in the cytoplasm. This protein is encoded by a gene and forms the 39S ribosome together with 39S ribosomal protein L2 (rpL2). 39S r

Protein Name: Mitochondrial Ribosomal Protein L19

More Common Targets